

Effects of carboxymethyl-glucan from *Saccharomyces cerevisiae* on the peripheral blood cells of patients with advanced prostate cancer

MARCIANE MAGNANI¹, RAUL HERNAN CASTRO-GOMEZ¹, MATEUS NOBREGA AOKI²,
EMERSON PEREIRA GREGÓRIO³, FARID LIBOS JR³ and MARIA ANGELICA EHARA WATANABE²

¹Departamento de Ciência e Tecnologia de Alimentos, and ²Departamento de Ciências Patológicas,
Universidade Estadual de Londrina; ³Instituto do Câncer de Londrina, Londrina, Paraná, Brasil

Received May 21, 2010; Accepted June 15, 2010

DOI: 10.3892/etm.2010.121

Abstract. Carboxymethyl-glucan (CM-G) is a water-soluble derivative of $\beta(1-3)(1-6)$ glucan that is well known for its immunostimulant and hematopoiesis-enhancing activities. In this clinical trial, we assessed the effects of oral CM-G administration on the peripheral blood cells of patients with advanced prostate cancer, and examined its ability to alter hepatic and renal function. After CM-G administration, the total leukocyte count increased significantly ($p \leq 0.02$), with no associated changes in the lifestyle habits of the patients. A significant increase ($p \leq 0.001$) was also observed for red blood cell, hematocrit, hemoglobin and platelet counts. No changes were observed in hepatic or renal function after CM-G administration, and no side effects associated with its use were recorded. These results suggest that using CM-G as an adjuvant to cancer treatment may improve the health parameters of prostate cancer patients.

Introduction

The β -glucans are of particular interest to researchers because they are naturally occurring glucose polymers, are orally active when taken as food supplements, and have a long track record of safe use. Due to their immunomodulatory properties, purified β -glucans have been used clinically as part of a combination therapy for a variety of cancers (1).

Carboxymethyl-glucan (CM-G) is a water-soluble derivative of the *Saccharomyces cerevisiae* cell wall $\beta(1-3)(1-6)$ glucan. It is classified as a biological response modifier and is well known for its immunomodulatory and hematopoiesis-enhancing activities (2-4). Several experimental studies *in vivo*

have shown that β -glucans administered orally, intravenously or enterally enhance hematopoietic regeneration without side effects (5-8).

Prostate cancer is the sixth most common cancer in the world and represents approximately 10% of all cancers diagnosed. In Brazil, prostate cancer is the most common type of cancer in males (excluding non-melanoma skin cancer), and is prevalent in all regions of the country. More than any other type of cancer, prostate cancer is considered a disease of the elderly, since nearly three-fourths of the cases worldwide occur at the age of 65 or above (www.inca.gov.br) (9).

While a man with localized prostate cancer is more likely to die from comorbidities, the probability of death from prostate cancer exceeds other causes when clinical metastases occur. Metastatic prostate cancer remains incurable, and it is known that many parameters of immunity decline with age (10). At this stage, the medical goals are to increase the short survival period of the patients and, above all, to improve their quality of life, which often declines as the disease progresses.

Considering the beneficial properties ascribed to CM-G and its potential use as an adjuvant to cancer treatment, we assessed *in vivo* the effects of oral CM-G administration on the peripheral blood cells of patients with advanced prostate cancer (PCa) and on alterations in hepatic and renal functions.

Patients and methods

This study was conducted with the approval of the Committee on Ethical Research Involving Human Beings of the University of Londrina and the Northern State of Paraná University Hospital. CONEP 268 and 212/07 for this project are available under registration no. 0214.0.268.000-07 at the National Information on Ethics in Research Involving Human Beings, Brazil (SISNEP). Patients at the Londrina Cancer Institute with a histological diagnosis of stage T3 ($n=15$) and T4 ($n=15$) prostate adenocarcinoma according to TNM staging (www.cancerstaging.org) and undergoing androgen deprivation therapy (ADT) with goserelin acetate or leuprolide were included in this study after giving written informed consent. The age of the patients ranged from 52 to 84 years, with a median age of 69 years. The ADT treatment duration ranged

Correspondence to: Dr Marciane Magnani, Departamento de Ciência e Tecnologia de Alimentos, Universidade Estadual de Londrina, Rod Celso Garcia Cid, PR 445, Km 380, Campus Universitário, C.P. 6001, CEP 86051-990, Londrina, Paraná, Brasil
E-mail: magnani2@gmail.com

Key words: β -glucan, prostate cancer, blood cells




Figure 1. Leukocyte counts before and after CM-G treatment for 28 days. 1 and 2, total leukocytes before and after CM-G treatment; 3 and 4, neutrophils before and after treatment; 5 and 6, typical lymphocytes before and after treatment; 7 and 8, monocytes before and after treatment. A significant increase in total leukocytes was observed after treatment (* $p \leq 0.02$).

from 5 to 36 months. Among the 30 patients studied, 9 underwent radiation before ADT, 8 were smokers and 8 consumed alcohol regularly. During the 28-day treatment, patients were contacted weekly in order to monitor their conditions and to receive reports of any adverse effects associated with the CM-G treatment.

Soluble β -glucan in the carboxymethylated (CM-G) form was obtained from the cell wall of *Saccharomyces cerevisiae*, according to the protocol described by Magnani *et al* (11). The CM-G was distributed into gelatin capsules containing 20 mg of CM-G with starch as an excipient vehicle. This procedure was carried out under medical request by Vico Farma®, which is registered at the National Health Surveillance Agency (ANVISA) in Brazil under no. 136420-0.

Peripheral venous blood samples were drawn for initial values from the patients early in the morning of Day 1 before the patients ingested the first capsule of CM-G. Early every morning, before eating, the patients ingested a 20-mg CM-G capsule (12). After 28 days, the blood samples were analyzed. Both samples were collected while patients were fasting. Vacutainer™ tubes (4.5 ml) containing EDTA were used, and all the samples were processed immediately after collection by the Abbott Cell Dyn 3200 flow cytometer.




Figure 2. Variations in hematological data before and after CM-G treatment for 28 days. Patients were divided according to their initial erythrocyte, hemoglobin and hematocrit counts into groups below or above the reference limit. 1 and 2, variations in erythrocyte levels in the below and above reference limit groups; 3 and 4, variations in hemoglobin levels in the below and above reference limit groups; 5 and 6, variations in hematocrit levels in the below and above reference limit groups. Patients who were below the reference limit (* $p \leq 0.001$) had significantly elevated values for all three parameters.

The results obtained before and after CM-G treatment for each patient were analyzed using the Wilcoxon signed-rank test and the t-test for dependent paired samples. $p \leq 0.05$ indicated significant differences.

Results

After CM-G administration, the total leukocyte counts increased significantly ($p \leq 0.02$), averaging a 10.64% increase. In the differential count, an increasing trend for typical lymphocytes, monocytes and neutrophils was observed (Fig. 1). The lifestyle habits of patients, such as smoking and alcohol use, were not associated with increased leukocytes.

The leukocyte counts carried out before CM-G administration showed that no patients had leukopenia. However, leukocyte levels closer to the minimum reference value ($3,500/\text{mm}^3$) were observed among patients who had received radiation. For these patients, CM-G administration resulted in an 11% increase in the values.

Table I. Results of liver and kidney function tests performed before and after carboxymethyl-glucan (CM-G) administration for 28 days in patients with advanced prostate cancer.

	Before CM-G	After CM-G	Reference value (method)
Liver function			
Transaminase aspartate amino transferase (TGO)	20.1 \pm 2.0	20.9 \pm 2.0	11-41 U/l (automated kinetics)
Transaminase alanine amino transferase (TGP)	9.2 \pm 0.9	9.4 \pm 0.8	7-52 U/l (automated kinetics)
Albumin	4.10 \pm 0.75	4.20 \pm 0.50	3.35-5.62 g/dl (capillary electrophoresis)
Direct bilirubin	0.08 \pm 0.01	0.07 \pm 0.02	Up to 0.3 mg/dl (colorimetric)
Indirect bilirubin	0.32 \pm 0.26	0.31 \pm 0.13	Up to 0.7 mg/dl (colorimetric)
Alkaline phosphatase	40.2 \pm 12.0	39.9 \pm 9.0	27-100 U/l (automated kinetics)
Kidney function			
Urea	39 \pm 10	38 \pm 10	10-52 mg/dl (automated enzymatic)
Creatinine	0.87 \pm 0.21	0.89 \pm 0.23	1.30 mg/dl (automated kinetics)

Before CM-G administration, 9 of the 30 patients studied had red blood cell counts below the minimum reference value ($4.3/\text{mm}^3$), 14 patients had hemoglobin levels below normal values (12.8 g/dl) and 10 patients had hematocrit values below the minimum reference value (38.8%). After 28 days of CM-G ingestion, significant increases ($p \leq 0.001$) in red blood cell, hematocrit and hemoglobin levels were observed; this increase was more pronounced in patients who were initially below the minimum (Fig. 2).

There were no significant changes in VCM, HCM, CHCM and RDW; however, the platelet counts increased significantly after treatment with CM-G ($p=0.007$).

No changes in kidney and liver function were found in association with CM-G administration (Table I), and no CM-G-related side effects were observed.

Discussion

CM-G stimulates reticuloendothelial system function and modulates cellular and humoral immunity (2,13,14). In its soluble form, β -glucan acts synergistically with *in vivo* myeloid growth factors, improving hematopoietic recovery and mobilizing progenitor cells in the peripheral blood (14). According to Rice *et al* (15), orally administered soluble derivatives of β -glucan are absorbed through the gastrointestinal wall and pass into the circulation system, activating immune pathways such as Dectin-1, CR-3, SIGNR1, TLR-2/6 and -4 (16).

Cancer-induced immunosuppression is a well-known phenomenon (12), but was not observed among the patients in this study. However, the standard treatment for advanced PCa is hormone therapy (17) and not chemotherapy, which is usually associated with leukopenia. By contrast, low white blood cell counts were observed prior to CM-G treatment in patients who had received radiation therapy. CM-G has proven effective in stimulating hematopoiesis after repeated doses of radiation, and in increasing granulocytes and other hematopoietic indices (18). Several experimental models have demonstrated the ability of β -glucans and derivatives administered by different routes to raise blood cell counts after leukopenia caused by cancer treatments (2,6,19).

The increase in leukocyte counts reported in this study supports the findings of Weitberg *et al* (20) regarding increases in white blood cells after oral β -glucan administration, and those of De Felipe *et al* (5), who found an increase in leukocytes at the expense of neutrophils, lymphocytes and monocytes on the fifth day of intravenous treatment. By contrast, Demir *et al* (12) observed no changes in leukocyte counts after 14 days of oral β -glucan administration. Although only the increase in leukocytes was significant in the present study, typical lymphocytes, monocytes and neutrophils clearly showed an increasing trend with CM-G treatment.

In the present study, no side effects associated with the ingestion of CM-G were observed. These results are in agreement with the findings of Demir *et al* (12), who observed no adverse effects of the daily oral administration of 20 mg of soluble β -glucan from *S. cerevisiae* for 14 days in 20 patients with metastatic breast cancer. Weitberg (20) administered 15 mg of oral β -glucan daily to 20 patients with various types of advanced cancer for 6 months and also found no side effects.

The absence of a significant variation in the results of hepatic and renal function tests before and after CM-G treatment (Table I) are in agreement with the findings of De Felipe *et al* (5), who treated 11 septic patients with 100-240 mg of β -glucan from *S. cerevisiae* for 8 days.

Smoking is associated with increased numbers of leukocytes (21). This association was not observed among the smokers in this study, who showed no difference before or after CM-G administration compared to non-smokers.

After 28 days of treatment with CM-G, a significant increase in red blood cell, hemoglobin and hematocrit levels was confirmed. Previous studies have reported that β -glucan acts directly on the myeloid progenitors, which contribute to hematopoietic regeneration (2,22). Increased levels of hemoglobin in cancer patients treated with oral β -glucan have been reported by Wietberg (20). Moreover, Demir *et al* (12) found no significant differences in the hematocrit count after treatment with β -glucan.

Platelet numbers also increased significantly in the present study, which corresponded with the results of Weitberg (20), but not with those described by Demir *et al* (12). Differences between our results and those reported by Demir *et al* (11) may be related to the duration of β -glucan administration (28 days in the present study vs. 14 days in that of Demir *et al*).

Ever closer to clinical practice, the use of β -glucan as an adjuvant has been used effectively for decades in Japan, improving the quality of life of cancer patients and reducing side effects (23). The results of this study suggest that the use of CM-G may enhance the hematologic parameters of patients with prostate cancer, benefiting the body weakened by the disease and its treatments.

Acknowledgements

The authors thank the National Council for Scientific and Technological Development (CNPq-Brazil) for financial support in the form of a doctorate scholarship to M.M.

Reference

1. Thompson IJ, Oyston PC and Williamson DE: Potential of the beta-glucans to enhance innate resistance to biological agents. *Expert Rev Anti Infect Ther* 8: 339-352, 2010.
2. Hofer M and Pospisil M: Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors' results. *Int J Immunopharmacol* 19: 607-609, 1997.
3. Chen R and Seviour J: Medicinal importance of fungal β -(1-3) (1-6)-glucans. *Mycol Res* 3: 635-652, 2007.
4. Kubala L, Ruzickova J, Nickova K, *et al*: The effect of (1-3)- β -D-glucans, carboxymethylglucan and schizophyllan on human leukocytes *in vitro*. *Carbohydrate Res* 338: 2835-2840, 2003.
5. De Felipe J Jr, Freire CAR and Mendes NF: Celularidade do sangue periférico após o emprego da glucana, um imunoeestimulante de s.r.e., em pacientes sépticos e em voluntários sem infecção. *Artigos Farmácia Virtual: www.pureessence.com.br/conteudo/con_artigo_glucana.html*. Accessed May 16, 2010.
6. Vetvicka V, Dvorak B, Vetvickova J, *et al*: Orally administered marine (1-3)-beta-D-glucan phycarine stimulates both humoral and cellular immunity. *Int J Biol Macromol* 40: 291-298, 2007.
7. Baran J, Allendorf DJ, Hong F and Gordon RD: Oral β -glucan adjuvant therapy converts nonprotective Th2 response to protective Th1 cell mediated immune response in mammary tumor-bearing mice. *Folia Histochem Cytobiol* 45: 107-114, 2007.
8. Liu J, Gunn L, Hanses R and Yan J: Combined yeast-derived β -glucan with anti-tumor monoclonal antibody for cancer immunotherapy. *Exp Mol Pathol* 86: 208-214, 2009.

9. Jemal A, Siegel R and Ward E: Cancer Statistics. *Cancer J Clin* 58: 71-96, 2008.
10. Pawelec G, Lustgarten J, Ruby C and Gravekamp C: Impact of aging on cancer immunity and immunotherapy. *Cancer Immunol Immunother* 58: 1907-1908, 2009.
11. Magnani M, Calliari CM, de Macedo FC Jr, *et al*: Optimized methodology for extraction of (1-3)(1-6)- β -D-glucan from *Saccharomyces cerevisiae* and in vitro evaluation of the cytotoxicity and genotoxicity of the corresponding carboxymethyl derivative. *Carbohydrate Polym* 78: 658-665, 2009.
12. Demir G, Klein HO, Mandel-Molinas N and Tuzuner N: β -glucan induces proliferation and activation of monocytes in peripheral blood of patients with advanced breast cancer. *Int Immunopharm* 7: 113-116, 2007.
13. Darpossolo FPB, Quintana LR, Magnani M, *et al*: Evaluation of potential immunostimulant of the Carboxymethyl-glucan from *Saccharomyces cerevisiae* in poultry (*Gallus domesticus*). *Semina* 31: 231-240, 2010.
14. Patchen ML, Vaudrain T, Correia H, *et al*: In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. *Exp Hematol* 26: 1247-1254, 1998.
15. Rice PJ, Adams EL, Ozment-Skelton T, *et al*: Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. *J Pharmacol Exp Ther* 314: 1079-1086, 2005.
16. Brown GD and Gordon S: Immune recognition of fungal. *Cell Microbiol* 7: 471-479, 2005.
17. Fleming MT, Sonpavde G, Kondagunta GV, *et al*: Systemic therapy and novel agents for metastatic castration resistant prostate cancer. *Update Cancer Ther* 3: 133-145, 2009.
18. Pospisil M, Sandula J, Pipalova I, *et al*: Hemopoiesis stimulating and radioprotective effects of carboxymethylglucan. *Physiol Res* 40: 377-380, 1991.
19. Harada T, Kawaminami H, Miura NN, *et al*: Mechanism of enhanced hematopoietic response by soluble β -glucan SCG in cyclophosphamide-treated mice. *Microbiol Immunol* 50: 687-700, 2006.
20. Weitberg A: A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. *J Exp Clin Cancer Res* 27: 40, 2008.
21. Lebailly P, Vigreux C, Lechevrel C, *et al*: DNA damage in mononuclear leucocytes of farmers measured using the alkaline comet assay: modifications of DNA damage levels after a one day field spraying period with selected pesticides. *Cancer Epidemiol Biomarkers Prev* 7: 929-940, 1998.
22. Turnbull JL, Patchen ML and Scadden DT: The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. *Acta Haematol* 102: 66-71, 1999.
23. Hamuro J: Anticancer immunotherapy with perorally effective lentinan. *Gan To Kagako Royo* 32: 1209-1215, 2005.